^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Puyouheng (pucotenlimab)

    i
    Other names: HX008, HX 008, HX-008
    Company:
    HanX Biopharma, Lepu Med, Taizhou Hanzhong Biopharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    15d
    MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC (clinicaltrials.gov)
    P2, N=60, Recruiting, Fudan University
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    1m
    A Multicenter, Single-Arm, Open-Label Clinical Study of Cetuximab Beta in Combination with Pucotenlimab and Chemotherapy as Neoadjuvant Therapy for KRAS/NRAS Wild-Type Left-Sided Colon Cancer and Upper Rectal Cance (ChiCTR2500110202)
    P2, N=53, Not yet recruiting, The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • Puyouheng (pucotenlimab)
    1m
    A Prospective, Single-Arm, Multi-Center Exploratory Clinical Study of Neoadjuvant Pucotenlimab Combined with Cetuximab and Albumin-Bound Paclitaxel Followed by Sequential Radiotherapy for Locally Advanced Hypopharyngeal Cancer (ChiCTR2500107566)
    P4, N=26, Not yet recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Erbitux (cetuximab) • albumin-bound paclitaxel • Puyouheng (pucotenlimab)
    2ms
    Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Sun Yat-sen University
    New trial
    |
    Lenvima (lenvatinib) • irinotecan • Puyouheng (pucotenlimab)
    3ms
    Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT) (clinicaltrials.gov)
    P2, N=68, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Initiation date: Jan 2025 --> Aug 2024
    Enrollment open • Trial initiation date
    |
    Puyouheng (pucotenlimab)
    3ms
    IDEAL: Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou | Initiation date: Jun 2025 --> Oct 2025
    Trial initiation date
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4ms
    An Exploratory, Multicenter Clinical Study of Cetuximab in Combination with Pucotenlimab and Nab-Paclitaxel for the Treatment of Recurrent or Metastatic Hypopharyngeal Cancer (ChiCTR2500107182)
    P4, N=32, Not yet recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Erbitux (cetuximab) • albumin-bound paclitaxel • Puyouheng (pucotenlimab)
    4ms
    Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=59, Recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Jiataile (sacituzumab tirumotecan)
    4ms
    Exploring the safety and efficacy of sacituzumab tirumotecan combined with pucotenlimab in the treatment of advanced cholangiocarcinoma (ChiCTR2500105431)
    P2, N=53, Recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Jiataile (sacituzumab tirumotecan)
    4ms
    Pucotenlimab Combined with Chemotherapy and Lenvatinib as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial (ChiCTR2500103869)
    P2, N=47, Not yet recruiting, Department of oncology, Beijing Friendship Hospital, Capital Medical University; Department of oncology, Beijing Friendship Hospital, Capital Medical
    New P2 trial
    |
    cisplatin • carboplatin • Lenvima (lenvatinib) • albumin-bound paclitaxel • Puyouheng (pucotenlimab)
    4ms
    Preoperative short-term radiotherapy combined with Pucotenlimab for advanced soft tissue sarcoma of the limbs and trunk-a single cohort pilot study (ChiCTR2500104524)
    P=N/A, N=10, Recruiting, The First Affiliated Hospital, Air Force Medical University; The First Affiliated Hospital, Air Force Medical University
    New trial
    |
    Puyouheng (pucotenlimab)
    4ms
    Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • Puyouheng (pucotenlimab)